PRQR ProQR Therapeutics N.V.
$1.86▼ -4.12%
Healthcare
Other
After hours
$1.93▲ +3.76%
Sep 11, 7:58 PM ET
Volume 579.2K
Avg Volume (10D) 660.0K
Key Metrics & Fundamentals
Market Cap
$262.48M
P/E Ratio
–
Div Yield
–%
52W Range
1.33 - 3.10
% vs 50 MA
-3.43%
% vs 200 MA
4.27%
RSI-14
37.8
MACD Histogram
-0.0600
Beta (1Y vs SPY)
1.72
Free Cash Flow
-$12.56M
Gross Rev
$8.76M
Gross Profit
$8.76M
EBITDA
-$8.12M
COGS
–
Operating Exp
$17.58M
Operating Income
-$8.82M
EBIT
-$8.82M
Pretax Income
-$8.70M
Net Income
-$8.73M
Price & Volume History
Loading chart…
Recent News
ProQR Therapeutics Doses First Participant in Phase 1 Trial of Liver Disease Treatment
MT Newswires · Sep 9, 2026 1:23 PM
ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026
GlobeNewswire · Sep 9, 2026 12:00 PM
ProQR to Participate in Upcoming Investor Conferences in September 2026
GlobeNewswire · Sep 2, 2026 12:00 PM
ProQR: Q2 Earnings Snapshot
Associated Press · Aug 14, 2026 4:46 PM
Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates
Zacks · Aug 14, 2026 12:25 PM
ProQR Announces Second Quarter 2026 Operating and Financial Results
GlobeNewswire · Aug 13, 2026 11:00 AM
Proqr Therapeutics Insider Bought Shares Worth $353,960, According to a Recent SEC Filing
MT Newswires · Aug 3, 2026 8:27 PM
ProQR Registers Shares for Resale by Investor
MT Newswires · Jul 6, 2026 9:38 PM
Chardan Research Adjusts ProQR Therapeutics Price Target to $3 From $4, Maintains Buy Rating
MT Newswires · Jun 26, 2026 12:17 PM
ProQR Therapeutics Says Phase 1 Trial of Liver Drug Candidate Meets Primary Endpoint
MT Newswires · Jun 25, 2026 11:23 AM
Financial Overview - Income Statement
Quarterly
Jun 2026
See PRQR's money flow as a full page
Social Sentiment
No Reddit posts found for PRQR.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.